Integrating single-cell biophysical and transcriptomic features to resolve functional heterogeneity in mantle cell

Ye Zhang1, Lydie Debaize2, Adam Langenbucher3

  • 1Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA.

Science Advances
|December 5, 2025
PubMed

Insights

Single-cell biophysical properties like buoyant mass and stiffness can identify cancer cell phenotypes. These properties correlate with treatment response, offering new biomarkers for precision medicine in B cell malignancies.

Area of Science:

  • Biophysics
  • Oncology
  • Cell Biology

Background:

  • Intratumor heterogeneity complicates cancer progression and treatment resistance.
  • Conventional methods struggle to fully characterize cellular diversity.
  • Single-cell biophysical properties offer complementary insights into functional phenotypes.

Purpose of the Study:

  • To link single-cell biophysical properties (buoyant mass, stiffness) to gene expression in mantle cell lymphoma (MCL).
  • To identify clinically relevant phenotypes within MCL cells.
  • To explore the potential of biophysical properties as biomarkers for therapeutic response.

Main Methods:

  • Linked measurements of buoyant mass, stiffness, and gene expression in MCL cells.
  • Analysis of primary patient specimens ex vivo.
  • Correlation of biophysical properties with sensitivity to Bruton's tyrosine kinase inhibitors.

Main Results:

  • Buoyant mass and stiffness characterize B cell development states and correlate with oncogenic signaling genes (e.g., BLK, CD79A).
  • Changes in cell buoyant mass in patient samples correlate with ex vivo sensitivity to Bruton's tyrosine kinase inhibitors.
  • These biophysical properties are relevant in both mantle cell lymphoma and chronic lymphocytic leukemia.

Conclusions:

  • Single-cell biophysical properties provide valuable biomarkers for understanding cancer heterogeneity.
  • Buoyant mass and stiffness can predict response to targeted therapies like Bruton's tyrosine kinase inhibitors.
  • Biophysical profiling holds promise for advancing precision therapeutic strategies in B cell malignancies.